Global coagulation assays in transgender women on oral and transdermal estradiol therapy.

Abstract

The thrombotic effects of estradiol therapy in transgender women are unclear. Global coagulation assays (GCA) may be better measures of hemostatic function compared to standard coagulation tests. To assess the GCA profiles of transgender women in comparison to cisgender controls and to compare how GCA differ between routes of estradiol therapy in transgender women. Cross-sectional case-control study. General community. Transgender women, cisgender male and cisgender female controls. Citrated blood samples were analyzed for (i) whole blood thromboelastography (TEG®5000), (ii) platelet-poor plasma thrombin generation (calibrated automated thrombogram); and (iii) platelet-poor plasma fibrin generation (overall hemostatic potential assay). Mean difference (95% confidence intervals) between groups are presented. Twenty-six transgender women (16 oral estradiol, 10 transdermal estradiol) were compared to 98 cisgender women and 55 cisgender men. There were no differences in serum estradiol concentration (p=0.929) and duration of therapy (p=0.496) between formulations. Transgender women demonstrated hypercoagulable parameters on both thromboelastography (maximum amplitude +6.94mm (3.55, 10.33), p<0.001) and thrombin generation (endogenous thrombin potential +192.62nM.min (38.33, 326.91), p=0.009; peak thrombin +38.10nM (2.27, 73.94), p=0.034) but had increased overall fibrinolytic potential (+4.89% (0.52, 9.25), p=0.024) compared to cisgender men. No significant changes were observed relative to cisgender women. Route of estradiol delivery or duration of use did not influence the GCA parameters. Transgender women on estradiol therapy demonstrated hypercoagulable GCA parameters compared to cisgender men with a shift towards cisgender female parameters. Route of estradiol delivery did not influence the GCA parameters.